Business

Update on Elective Surgery and Customer Orders

Update on Elective Surgery and Customer Orders.

articleRua Life Sciences PlcJune 8, 20205/company/rua-life-sciences-plc/news/update-on-elective-surgery-and-customer-orders
Update on Elective Surgery and Customer Orders

About this update from Rua Life Sciences Plc

[{"type":"text","content":"\n \n \n RNS Number : 1712P\n AorTech International PLC\n 08 June 2020\n  \n \n \n \n AorTech International plc\n \n \n (\"AorTech\", the \"Company\" or the \"Group\")\n \n \n Update on Elective Surgery and Customer Orders\n \n \n AorTech International plc (AIM: AOR.L), the holding company of a group of medical device businesses focused on the exploitation of the world's leading long-term implantable biostable polymer (Elast-Eon\n \n \n TM\n \n \n ), provides the following update on customer orders received by its \n recently acquired\n  \n wholly-owned \n subsidiary, RUA Medical Devices Limited (\"RUA\").\n \n \n Resumption of Orders\n \n \n On 14 April 2020, AorTech announced that\n  \n RUA  had been notified by its largest customer that, due to US Government (both federal and state) mandates to suspend all elective surgery in hospitals and surgical centres throughout the United States, it was temporarily unable to provide forecasts and orders for the medical devices manufactured for it by RUA. RUA has recently received a further notification from its largest customer requesting it to prepare for the production of products and that orders would resume in the near future, but reserved the right to implement further suspension of orders in the event of the impact of a second wave of COVID-19. Since receipt of this notification, RUA has now received new orders from its largest customer\n  \n for delivery in August 2020.\n \n \n  \n \n \n David Richmond, Group CEO of AorTech, stated\n : \"We are encouraged by this recent communication and the resumption of orders by our largest customer but are mindful that a second wave of COVID-19 could still lead to a further suspension. We are now planning production schedules following the successful completion of a 'Safe working during COVID-19 pandemic' risk assessment. All active staff have been trained to ensure that they are able to work safely and comply with the UK Government's social-distancing guidelines. We look forward to being able to bring those members of staff back from furlough in-line with the production scheduling requirements.\"\n \n \n For further information contact:\n \n \n  \n \n \n AorTech International plc                                    \n \...

More updates from Rua Life Sciences Plc